Understand the source comparison
Best Peptides for Ankle Sprain: Recovery Agent Comparison
BPC-157 VEGF upregulation, angiogenesis, collagen alignment 200–500 mcg/day subcutaneous near injury site Subcutaneous, 2–3 inches from injury Reduces healing time by 30–40% in research models Best choice for acute ligament tears where vascularization is the r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, collagen alignment
- 200–500 mcg/day subcutaneous near injury site
- Subcutaneous, 2–3 inches from injury
- Reduces healing time by 30–40% in research models
- Best choice for acute ligament tears where vascularization is the rate-limiting step. Strongest evidence base for tendon/ligament repair
- TB-500
- Actin binding, cellular migration, reduced fibrosis
- 2–5 mg twice weekly intramuscular
- Intramuscular (systemic) or subcutaneous
- Improves collagen quality and reduces scar tissue formation by ~30%
- Ideal for systemic administration when multiple injury sites exist or injection site access is limited. Longer half-life than BPC-157
- Thymosin Beta-4
- Immune modulation, fibroblast support, collagen remodeling
- 5–10 mg twice weekly intramuscular
- Intramuscular (systemic)
- Reduces chronic stiffness by ~25% during remodeling phase
- Functionally similar to TB-500 but requires higher dosing. Consider for immune-compromised individuals or chronic overuse injuries
- MK 677
- Growth hormone secretagogue, IGF-1 elevation
- 10–25 mg/day oral
- Oral administration
- Indirect support via systemic GH/IGF-1. No direct ligament-specific mechanism
- Useful as adjunct therapy for general recovery and sleep quality, but not a first-line peptide for isolated ankle injury
- BPC-157 is the single most studied peptide for ligament and tendon repair, with over 30 peer-reviewed publications documenting its effects on connective tissue healing. TB-500 offers practical advantages for systemic dosing and broader anti-inflammatory effects. Thymosin Beta-4 serves as a second-line option when TB-500 isn't available or when immune modulation is a priority.